Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kaleido Biosciences Inc (KLDO)

Kaleido Biosciences Inc (KLDO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cellarity Expands Leadership Team to Continue Evolution of a Breakthrough Platform to Encode Biology and Purposefully Create New Medicines

Cellarity, a life sciences company founded by Flagship Pioneering to encode and simulate human biology to reimagine the way we create medicines, announced today the expansion of its executive leadership...

AXLA : 0.4009 (-8.89%)
CDAK : 0.0570 (-55.98%)
DNLI : 30.76 (+0.26%)
EVLO : 0.0001 (unch)
FHTX : 9.56 (-2.85%)
KLDO : 0.0001 (unch)
MRNA : 69.86 (-2.96%)
OMGA : 1.4300 (+5.15%)
RUBY : 0.0570 (+2.70%)
SANA : 4.29 (-0.23%)
MCRB : 1.0500 (-4.55%)
SGTX : 22.47 (-2.56%)
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis Congress

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated,...

KLDO : 0.0001 (unch)
Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan...

SRPT : 125.01 (-0.54%)
AXLA : 0.4009 (-8.89%)
CDAK : 0.0570 (-55.98%)
DNLI : 30.76 (+0.26%)
EVLO : 0.0001 (unch)
FHTX : 9.56 (-2.85%)
KLDO : 0.0001 (unch)
MRNA : 69.86 (-2.96%)
OMGA : 1.4300 (+5.15%)
RUBY : 0.0570 (+2.70%)
SANA : 4.29 (-0.23%)
MCRB : 1.0500 (-4.55%)
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated,...

KLDO : 0.0001 (unch)
Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform

Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics,...

AXLA : 0.4009 (-8.89%)
CDAK : 0.0570 (-55.98%)
DNLI : 30.76 (+0.26%)
EVLO : 0.0001 (unch)
FHTX : 9.56 (-2.85%)
KLDO : 0.0001 (unch)
MRNA : 69.86 (-2.96%)
OMGA : 1.4300 (+5.15%)
RUBY : 0.0570 (+2.70%)
SANA : 4.29 (-0.23%)
MCRB : 1.0500 (-4.55%)
SGTX : 22.47 (-2.56%)
Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer

LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated,...

KLDO : 0.0001 (unch)
Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship’s Pioneering Medicines to Treat Cystic Fibrosis

Tessera Therapeutics today announced a treatment-focused collaboration with the Cystic Fibrosis Foundation using Tessera’s Gene Writing technology to rewrite the genetic codes that cause cystic fibrosis....

AXLA : 0.4009 (-8.89%)
CDAK : 0.0570 (-55.98%)
DNLI : 30.76 (+0.26%)
EVLO : 0.0001 (unch)
FHTX : 9.56 (-2.85%)
KLDO : 0.0001 (unch)
MRNA : 69.86 (-2.96%)
OMGA : 1.4300 (+5.15%)
RUBY : 0.0570 (+2.70%)
SANA : 4.29 (-0.23%)
MCRB : 1.0500 (-4.55%)
SGTX : 22.47 (-2.56%)
Kaleido Biosciences Reports Third Quarter 2021 Financial Results

--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction...

KLDO : 0.0001 (unch)
Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated,...

KLDO : 0.0001 (unch)
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021

Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented

KLDO : 0.0001 (unch)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar